Casellini, Carolina M.
- Assistant Professor, Internal Medicine
Contact Info
Publications
selected publications
-
2019Development and Validation of the Norfolk Quality of Life Fatigue Tool (QOL-F): A New Measure of Perception of Fatigue.. Journal of the American Medical Directors Association.Full Text via DOI: 10.1016/j.jamda.2019.10.021 PMID: 31859222
-
2018Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. FRONTIERS IN NEUROSCIENCE.Full Text via DOI: 10.3389/fnins.2018.00591 PMID: 30210276
-
2017Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 102:4343-4410.Full Text via DOI: 10.1210/jc.2017-01922 PMID: 29126250
-
2016Bariatric Surgery Restores Cardiac and Sudomotor Autonomic C-Fiber Dysfunction towards Normal in Obese Subjects with Type 2 Diabetes. PLOS ONE. 11.Full Text via DOI: 10.1371/journal.pone.0154211 PMID: 27137224
-
2016Alternative Quantitative Tools in the Assessment of Diabetic Peripheral and Autonomic Neuropathy. CONTROVERSIES IN DIABETIC NEUROPATHY. 235-285.Full Text via DOI: 10.1016/bs.irn.2016.03.010 PMID: 27133153
-
2015Role of Peroxynitrite in the Development of Diabetic Peripheral Neuropathy. DIABETES CARE. e100-e101.Full Text via DOI: 10.2337/dc14-2918 PMID: 26106228
-
2015The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. FRONTIERS IN ENDOCRINOLOGY.Full Text via DOI: 10.3389/fendo.2015.00094 PMID: 26124748
-
2013Diabetic Neuropathy. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA. 42:747-+.Full Text via DOI: 10.1016/j.ecl.2013.06.001 PMID: 24286949
-
2013Sudoscan, a Noninvasive Tool for Detecting Diabetic Small Fiber Neuropathy and Autonomic Dysfunction. DIABETES TECHNOLOGY & THERAPEUTICS. 15:948-953.Full Text via DOI: 10.1089/dia.2013.0129 PMID: 23889506
-
2013Contact Heat-Evoked Potential Stimulation for the Evaluation of Small Nerve Fiber Function. DIABETES TECHNOLOGY & THERAPEUTICS. 15:150-157.Full Text via DOI: 10.1089/dia.2012.0202 PMID: 23298343
-
2013Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. JOURNAL OF DIABETES INVESTIGATION. 4-18.Full Text via DOI: 10.1111/jdi.12042
-
2007A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. DIABETES CARE. 30:896-902.Full Text via DOI: 10.2337/dc06-1699 PMID: 17392551
-
2007Clinical Manifestations and Current Treatment Options for Diabetic Neuropathies. ENDOCRINE PRACTICE. 13:550-566.Full Text via DOI: 10.4158/ep.13.5.550
-
2006Pioglitazone treatment improves nitrosative stress in type 2 diabetes.. DIABETES CARE. 29:869-76.Full Text via DOI: 10.2337/diacare.29.04.06.dc05-0517 PMID: 16567830
-
2006Recent advances in the treatment of diabetic neuropathy. Current Opinion in Internal Medicine. 5:260-266.Full Text via DOI: 10.1097/01.med.0000216963.51751.be
-
2000
Research
projects
-
Current Project
- Hepatocyte Growth Factor (HGF) For Diabetic Neuropathy P.I. 2021 -
- Muscarinic Antagonists for Diabetic Neuropathy P.I. 2020 -
- Semaglutide for Cardiovascular Outcomes in Obese Subjects P.I. 2018 -
- Quality of Life (QOL) Tool to Examine Fatigue P.I. 2017 -
- Topiramate for Cryptogenic Sensory Peripheral Neuropathy (CSPN) P.I. 2018 - 2021
-
Grant
- A 12-Month, Adaptive, Phase 3, Double-Blind, Randomized, Placebo- Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants with Painful Diabetic Peripheral Neuropathy P.I. 2021 -
- A Randomized, Double-blind, Placebo-controlled, Parallel, 12-week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetes Mellitus Patients with Neuropathy P.I. 2020 -
- SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity P.I. 2018 -
- Utilizing a Quality of Life (QOL) Tool to Examine Fatigue in Cognitive and Physical Contexts P.I. 2017 -
- National Institutes of Health/National Institute of NeurTopiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN) P.I. 2018 - 2021
- The Effects of Liraglutide on SUDOMOTOR Function and Inflammation in Type 2 Diabetes P.I. - 2020
- Impact of Timed Bromocriptine-QR Therapy upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects P.I. - 2018
- Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy P.I. - 2018
- Development of a Quality of Life Tool Sensitive to Cognitive and Physical Measures of Fatigue P.I. - 2016
- Impact of Supervised vs. Home-Based Exercise Training on Gait, Balance, and Falls Risk in Type 2 Diabetes P.I. - 2016
- Peroxynitrite, Protein Nitration, and Peripheral Diabetic Neuropathy P.I. - 2015
-
Past Project
- The Effects of Liraglutide on SUDOMOTOR Function and Inflammation in Type 2 Diabetes P.I. - 2020
- Impact of Timed Bromocriptine-QR Therapy upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects P.I. - 2018
- Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy P.I. - 2018
- Development of a Quality of Life Tool Sensitive to Cognitive and Physical Measures of Fatigue - 2016
- Impact of Supervised vs. Home-Based Exercise Training on Gait, Balance, and Falls Risk in Type 2 Diabetes - 2016
- Peroxynitrite, Protein Nitration, and Peripheral Diabetic Neuropathy P.I. - 2015
Contact
full name
- Carolina M. Casellini
